Recent Analysts’ Ratings Changes for HealthEquity (HQY)

Several brokerages have updated their recommendations and price targets on shares of HealthEquity (NASDAQ: HQY) in the last few weeks:

• 9/18/2026 – HealthEquity had its price target raised by Barclays PLC from $110.00 to $115.00. They now have an “overweight” rating on the stock.
• 9/16/2026 – HealthEquity was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 9/5/2026 – HealthEquity was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/3/2026 – HealthEquity had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 9/2/2026 – HealthEquity had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 8/31/2026 – HealthEquity had its price target raised by Deutsche Bank Aktiengesellschaft from $135.00 to $142.00. They now have a “buy” rating on the stock.
• 8/28/2026 – HealthEquity was given a new $111.00 price target by Telsey Advisory Group.
• 8/28/2026 – HealthEquity had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/28/2026 – HealthEquity had its “buy” rating reaffirmed by BTIG Research. They now have a $115.00 price target on the stock.
• 8/22/2026 – HealthEquity was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/8/2026 – HealthEquity was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Activity

In other news, EVP Michael Fiore sold 2,470 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total value of $234,650.00. Following the transaction, the executive vice president owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of HealthEquity stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the sale, the director owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. This represents a 10.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 12,456 shares of company stock worth $1,256,664. 1.60% of the stock is owned by company insiders.

HealthEquity, Inc provides technology-enabled services for consumer-directed benefits and healthcare savings accounts. The company helps employers, benefits advisors and individuals manage tax-advantaged accounts, including health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), commuter benefits and other employee benefit programs.

Its offerings include account administration, payment cards, reimbursement services, benefits communication, compliance support, healthcare spending tools and investment options for eligible HSA funds.